PRIMA BIOMED ANNOUNCES FIRST CLINICAL DATA FROM COMBINATION OF IMP321 WITH ANTI-PD1
December 22nd 2016
PRIMA BIOMED ANNOUNCES DATA FROM IMP321 AIPAC CLINICAL TRIAL IN BREAST CANCER
December 5th 2016
PRIMA BIOMED ENTERS INTO SALE AND LICENSING AGREEMENT WITH SYDYS TO ADVANCE CVAC™ PROGRAM
October 13th 2016
PRIMA TO PRESENT AT 2016 SOCIETY FOR IMMUNOTHERAPY OF CANCER CONFERENCE
October 6th 2016
PRIMA ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT ESMO SYMPOSIUM ON IMMUNO-ONCOLOGY
August 18th 2016
Operational Update
August 10th 2016
PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY
July 12th 2016
PRIMA BIOMED COLLABORATES IN INVESTIGATOR SPONSORED NEW CLINICAL TRIAL FOR IMP321 IN SOLID TUMORS
July 6th 2016
PRIMA BIOMED TO MAINTAIN NASDAQ LISTING
June 22nd 2016
PRIMA BIOMED ANNOUNCES FIRST SAFETY, PHARMACOKINETICS AND IMMUNO-MONITORING DATA FROM PHASE IIB CLINICAL TRIAL OF IMP321
March 15th 2016
IMP321 SAFETY AND IMMUNE MONITORING DATA PUBLISHED IN CLINICAL CANCER RESEARCH JOURNAL
March 4th 2016
PRIMA BIOMED RECEIVES NASDAQ NOTICE OF BID PRICE DEFICIENCY
March 2nd 2016
Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial
February 5th 2016
JAPANESE PATENT GRANTS FOR IMP321 IN CANCER
January 28th 2016
US PATENT GRANTS FOR IMP731 ANTIBODY
January 27th 2016
PRIMA BIOMED INITIATES PHASE I MELANOMA STUDY IN AUSTRALIA
We use cookies and other tracking technologies to improve your browsing experience on our website, to analyze our website traffic, and to understand where our visitors are coming from. By browsing our website, you consent to our use of cookies and other tracking technologies. To learn more about cookies view ourPrivacy policy
